positron emission tomography scan

Displaying 43 studies

  • Young-adult normal FDG-PET database Rochester, MN

    The purpose of this study is to construct a young-adult normative FDG database that could be used with Cortex-ID and/or MIMneuro, enabling a quantifiable regional cortex map by using a single patient’s FDG scan. Here, we will conduct a preliminary study (n=10) to test the feasibility of the protocol and workflow.

  • A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects with Parkinson's Disease (PD) from other Movement Disorders Scottsdale/Phoenix, AZ

    The purpose of this study is to determine whether 18F-AV-133 PET scans can be used to differentiate subjects with Parkinson's Disease from other movement disorders.

  • A Study Using Octreotide Scan versus PET Scan in the Diagnosis and Follow-up of Patients with Carcinoid and Neuroendocrine Tumors Scottsdale/Phoenix, AZ

    The purpose of this study is to determine if octreotide scans are more sensitive than PET scans for diagnosing carcinoid or neuroendocrine tumors.

  • AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients Rochester, MN

    AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

  • PET Scan Imaging in Assessing Response in Patients with Esophageal Cancer Receiving Combination Chemotherapy Rochester, MN

    RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.

    PURPOSE: This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.

  • PET (Positron Emission Tomography) Imaging Studies With NIS Reporter Rochester, MN

    The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).

  • Bridging Study of C11 PiB and F18 Flutemetamol Brain PET Rochester, MN

    The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with AD or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the ...

  • A Study to Evaluate Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction Rochester, MN


    The aims of this research project are to assess the effectiveness of motion correction software for patients undergoing PET brain scans, to assess the data acquisition and image processing workflow for parametric analysis of brain and whole body scans, and to assess the quality of PET images reconstructed with maximum a posteriori (MAP) reconstruction algorithm.

  • Inflammation of the Heart Muscle Tissue in Patients with Rheumatoid Arthritis Rochester, MN

    Rheumatoid arthritis (RA) patients have a higher prevalence of subclinical atherosclerosis than the general population. In addition, they experience higher rates of heart failure with preserved ejection fraction (HFpEF). There is evidence that myocardial mechanics and left ventricular diastolic function are more abnormal in the RA population and these changes occur earlier than in the general population. Recently a study suggested that RA patient have abnormal myocardial inflammation during a disease flare and that this is improved with anti-inflammatory treatment. Our study is aimed at describing the prevalence of myocardial inflammation in patients during active RA disease flares and comparing ...

  • Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline Scottsdale/Phoenix, AZ

    This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

  • TRC-PAD Program: In-Clinic Trial-Ready Cohort Rochester, MN; Jacksonville, FL

    The purpose of this study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstudy.org/welcome).

  • A Study to Evaluate Long Term Change in Tau Deposits by Comparing New Scans with 18F-AV-1451 Uptake, to Scans from Previous Study 18F-AV-1451-A05 Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate long term change in tau deposits, measured by comparing new scans of 18F-AV-1451 uptake to scans from a previous study.

  • A Study to Assess Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia Rochester, MN

    This study is designed to learn more about the use of a new imaging agent AV-1451 which shows strong binding to abmormal tau in the brain, to see if it will allow positron emission tomography (PET) scanning of tau in the brains of patients with Primary Progressive Aphasia.

  • Prognostic value of Aβ Imaging in NPH Prior to Shunt Placement Jacksonville, FL

    In this pilot study the investigators shall prospectively in a blinded fashion evaluate with AB PET and CSF AB42 and tTau or pTau in patients committed to shunt surgery and then investigate the relationship of these biomarkers with outcome on gait, cognition and urinary control improvement in the short term (3 months) and long term (1 year). The imaging agent will be provided by AVID.

    Furthermore the study will standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.

  • PiB PET Scanning in Speech and Language Based Dementias Rochester, MN

    The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.

  • Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) Scottsdale/Phoenix, AZ

    A brain PET scan is recognized as "reasonable and necessary" for some patients with "a recently established diagnosis of dementia" (Centers for Medicare and Medicaid Services, Decision Memo CAG-00088R, 2004), but evidence is less clear for patients having less severe cognitive problems. A substantial portion of such patients will develop Alzheimer's disease and other forms of dementia, which affect millions of people in the U.S., costing us over $100 billion annually. This project employs a prospective randomized protocol to determine whether PET scanning can help distinguish those patients with early Alzheimer's changes in their brains from those having other causes ...

  • Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients with Tumor Induced Osteomalacia Rochester, MN

    This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor.

  • Tau PET Imaging in African Americans Jacksonville, FL; Rochester, MN

    The purpose of this study is to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.

  • Clinical Evaluation and Deployment of a Clinical PET/MR System with a Data Registry Jacksonville, FL

    The purpose of this study is to assess and deploy a new PET/MR platform following the same quality control method as was done at other Mayo Clinic sites, i.e. Rochester and Arizona.

    The secondary purpose is to initiate a data registry for the PET/MR studies allowing us to capture some basic information about the indications, findings, and relevant imaging and non-imaging biomarkers for the studies conducted. This will allow us to see trends in utilization as well as create preliminary data to inform future (IRB approved) investigations.

  • Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography Rochester, MN

    The primary objective of this study is to determine the correlation between the distribution of F-18 FES within ER+ breast tumors as seen on Positron Emission Mammography (PEM) images of the breast, and the distribution of cells stained ER+ within the tumor by immunohistochemistry (IHC) measurements at surgical pathology. The secondary aim is to determine if the correlation (or lack of) between F-18 FES uptake and F-18 FDG uptake as imaged by PEM, is an accurate representation of the heterogeneity of ER expression in the tumor.

  • 18F-DOPA-PET in Planning Surgery in Patients With Gliomas Rochester, MN; Scottsdale/Phoenix, AZ

    This pilot clinical trial studies fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) in planning surgery in patients with gliomas. New imaging procedures, such as 18F-DOPA-PET scan, may help find gliomas and may help in planning surgery.

  • PET imaging with [18F]BF4 Rochester, MN

    The objectives of the study are to determine the biodistribution of [18F]BF4 (TFB F 18 Injection) in patients with myeloma or endometrial cancer being treated with oncoviruses carrying the NIS reporter gene.

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol Jacksonville, FL; Rochester, MN

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

  • Clinical Protocol Development on a PET/MR System Scottsdale/Phoenix, AZ

    The objective of this pilot research protocol is to evaluate the quality of PET from the SIGNA PET/MR system and to compare the quantitative accuracy of PET images from the PET/MR system to PET images from a standard PET/CT system. 

  • The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Rochester, MN

    This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. We then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.

  • A Study to Evaluate Changes to the Design of an Improved Mammography Imaging Table Rochester, MN

    The purpose of this study is to evaluate if changes made to the design of the table used specifically for breast Positron Emission Mammography (PEM), will help improve the images of breast tissue close to the chest wall.

  • A Study of Breast Imaging with F-18 Fluoroestradiol in Patients with Newly Diagnosed ER+ Breast Cancer Rochester, MN

    The purpose of this study is to obtain additional high resolution images of your breast cancer using a Positron Emission Mammography (PEM) system. This system only allows us to image the breast, but provides higher quality and better resolution than those images we obtain with the PET/CT scanner.

  • Pilot Study on FDG PET/MRE for Stricture Assessment in Crohn’s Disease Rochester, MN

    Evaluation of TOF FDG PET-MRE for identification of predominantly fibrotic small bowel strictures in Crohn’s disease.

  • Evaluating FDG PET-MRI-based Biomarkers in Borderline Resectable Pancreatic Cancer Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    Aims, purpose, or objectives:

    1. Evaluation of quantitative biomarkers derived from simultaneous time-of-flight FDG PET-MRI/MRCP for assessment of response to neoadjuvant therapy in borderline resectable PDAC.
    2. Evaluate the comparative performance of blood and FDG PET-MRI/MRCP based biomarkers for assessment of response to neoadjuvant therapy in borderline resectable PDAC.

  • A Study Using Gallium-68 PSMA-11 and C-11 Choline PET Imaging to Detect Metastatic Prostate Cancer in Patients Rochester, MN

    Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will look at patients with suspected metastatic prostate cancer who have been imaged with 11C-Choline PET clinically and with PSMA PET (either Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 PSMA 1007) in order to demonstrate their utility in detecting prostate cancer.

  • FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia Rochester, MN

    This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.

  • FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy Rochester, MN

    This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may "light up" where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.

  • A Study of 68GA-PSMA-Gadoxetate PET/MR or PET/CT for Evaluation of Hepatocellular Carcinoma Rochester, MN

    The primary purpose of this trial is to demonstrate the feasibility of integrated 68Ga-PSMA-gadoxetate PET/MRI ot PET/CT for imaging patients with Hepatocellular Carcinoma (HCC), and to compare the accuracy of 68Ga-PSMA-gadoxetate PET/MRI with MRI for staging of HCC.

  • Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas Rochester, MN; Scottsdale/Phoenix, AZ

    The purpose of this study is to use a nutrient called 18F-FDOPA and PET/CT scan to help determine where and how big the tumor is, as well as how aggressive the tumor is. This will help treating physicians to target diseased areas with higher than standard doses of radiation, in order to improve the effectiveness of radiation in this tumor.

  • Study to Determine the Impact of Advanced Magnetic Resonance Imaging (MRI) Using 18F-DOPA (a chemical tracer that highlights certain cells during imaging) During Planning for Proton Beam Radiation Therapy. Scottsdale/Phoenix, AZ; Rochester, MN

    The purpose of this study is to utilize a novel approach of combining advanced radiation delivery with proton beam therapy with advanced tumor visualization with 18F-DOPA PET and MRI imaging. We will study the effectiveness and safety of this technique delivering the entire treatment over 1-2 weeks.

  • Clinical Evaluation Of MP26 Features in Adults Rochester, MN

    The purpose of the study is to collect representative clinical images (head and whole-body scans) of demonstrated diagnostic quality using the next-generation SIGNA PET/MR device equipped with investigational software components in adult population. The images and summary data from this study are intended for use in regulatory submission.

  • Genetic Biomarker Discovery for Metastatic Prostate Cancer Rochester, MN

    Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.

  • Comparison of MRI in the Evaluation of Multiple Myeloma Rochester, MN

    The purpose of this study is to compare the utility of whole body MRI (WBMRI) with diffusion-weighted imaging (DWI) and simultaneous 18F-FDG PET/MRI with time of flight (TOF) PET acquisition to identify and characterize osseous lesions in patients with multiple myeloma.

  • Breast Imaging with Positron Emission Mammography Rochester, MN

    The objective of this study is to determine if the diagnostic performance of a dedicated breast-specific positron emission mammography (PEM) system, is superior to that obtained with a conventional PET/CT scanner and capable of producing acceptable image quality at a low-radiation dose level.

  • Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma Scottsdale/Phoenix, AZ

    Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

  • 18F-fluciclovine PET Discrimination of Radiation Injury to the Brain Jacksonville, FL

    The goal of this study is to further evaluate the ability of fluciclovine PET to discriminate between radiation necrosis and tumor progression in patients with previously irradiated intracranial metastatic disease. 

  • A Study of Clinical Evaluation of a PET/MR System Rochester, MN

    The first objective of this pilot research protocol is to evaluate the quality of PET from the SIGNA PET/MR system and to compare the quantitative accuracy of PET images from the PET/MR system to PET images from a standard PET/CT system. The second objective of this pilot research protocol is to compare the image quality from MRI images acquired on the SIGNA PET/MR to clinical MR images acquired on a standard 3.0T MRI system.

  • A Study of Fluorine F 18 Fluorodopa-Labeled PET Scans for Planning Surgery and Radiation Therapy to Treat Patients who have Newly Diagnosed High- or Low-Grade Glioma Brain Cancer Tumors Rochester, MN

    The purpose of this study is to evaluate the use of fluorine F 18 fluorodopa-labeled PET scanning for the planning of surgery and radiation therapy to treat patients who have newly diagnosed high- or low-grade glioma brain tumors. New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scans, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment.

.

Mayo Clinic Footer